biguanide

DRUG3 trials

Sponsors

Tanabe Pharma Corporation, GlaxoSmithKline, Sanofi

Conditions

Diabetes MellitusType 2 Diabetes Mellitus

Phase 3

Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes

CompletedNCT01301833

Tanabe Pharma CorporationType 2 Diabetes Mellitus

Start: 2011-02-28End: 2012-09-30Updated: 2026-01-02

A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus

CompletedNCT01777282

GlaxoSmithKlineDiabetes Mellitus

Start: 2013-02-23End: 2015-01-27Updated: 2017-05-03

Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes

CompletedNCT01940965

SanofiType 2 Diabetes Mellitus

Start: 2013-09-30End: 2015-07-31Updated: 2015-08-04

Related Papers

Safety, tolerability and efficacy of lixisenatide in combination with oral antidiabetic treatment in Japanese patients with type 2 diabetes: An open-label, multicenter study.

2017-06-124 citations

Albiglutide, a weekly GLP-1 receptor agonist, improves glycemic parameters in Japanese patients with type 2 diabetes over 1 year when added to single oral antidiabetic drugs.

2016-12-216 citations